Digitoxin is a potential anticancer agent for several types of cancer

Medical Hypotheses

Volumn 53, Issue 6, 1999, Pages 543-548

  Haux, J ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTINEOPLASTIC AGENT; CARDIAC GLYCOSIDE; DIGITOXIN;

APOPTOSIS; CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; ENZYME INHIBITION; GLIOBLASTOMA; PRIORITY JOURNAL; REVIEW;

DIGITALIS;

EID: 0033383637     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0985     Document Type: Article

References (50)

1. Dasgupta A., Hart A. P. Rapid detection of oleander poisoning using fluorescence polarization immunoassay for digitoxin. Effect of treatment with digoxin-specific Fab antibody fragment (ovine). Am J Clin Pathol. 108:1997;411-416.
2. Jortani S. A., Helm R. A., Valdes R. Jr. Inhibition of Na, K-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem. 42:1996;1654-1658.
3. Moss R. W. Herbs Against Cancer. 1998;Equinox, New York. p. 242-248.
4. Shiratori O. Growth inhibitory effect of cardiac glycosides and aglycones on neoplastic cells: in vitro and in vivo studies. Gann. 58:1967;521-528.
5. Inada A., Nakanishi T., Konoshima T. Anti-tumor promoting activities of natural products. II. Inhibitory effects of digitoxin on two-stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors. Biol Pharm Bull. 16:1993;930-931.
6. Cassady J. M., Suffness M. Terpenoid antitumor targets. Cassady J. M., Douros J. D. Anti Cancer Agents Based on Natural Product Models. 1980;201-269 Academic Press, New York.
7. Stenkvist B., Bengtsson E., Eklund G. Evidence of a modifying influence of heart glucosides on the development of breast cancer. Anal Quant Cytol. 2:1980;49-54.
8. Stenkvist B., Bengtsson E., Eriksson O., Holmquist J., Nordin B., Westman-Naeser S. Cardiac glycosides and breast cancer. Lancet. 1:1979;563.
9. Stenkvist B., Pengtsson E., Dahlqvist B., Eriksson O., Jarkrans T., Nordin B. Cardiac glycosides and breast cancer, revisited. N Engl J Med. 306:1982;484.
10. Aromaa A., Hakama M., Hakulinen T., Saxen E., Teppo L., Ida lan-Heikkila J. Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int J Cancer. 18:1976;727-738.
11. LeWinn E. B. Cardiac glycosides and breast cancer. Lancet. 1:1979;96-97.
12. Friedman G. D. Digitalis and breast cancer. Lancet. 2:1984;875-875.
13. Goldin A. G., Safa A. R. Digitalis and cancer. Lancet. 1:1984;1134.
14. Bernstein L., Ross R. K. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case control study in Los Angeles County. Cancer Res. 52:1992;5510-5515.
15. Friedman-G. D., Coates-A. O., Potter J. D., Slattery M. L. Drugs and colon cancer. Pharmacoepidemiol Drug Saf. 7:1998;99-106.
16. Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol Rep. 6:1999;493-496.
17. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection ofphosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:1995;39-51.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:1983;55-63.
19. Haux J., Lam M., Marthinsen A. B. L., Strickert T., Lundgren S. Digitoxin, in non toxic concentrations, induces apoptotic cell death in Jurkat T cells in vitro. Z Onkol / J Oncol. 1:1999;14-20.
20. Haux J., Marthinsen A. B.L., Gulbrandsen M., Alfredsen A. S. Digitoxin sensitizes malignant breast cancer cells for radiation in vitro. Z Onkol / J Oncol. 1999.
21. Verheye Dua F. L., Böhm L. Na+,K+-ATPase Inhibitor oubain accentuates irradiation damage in human tumour cell lines. Radiat Oncol Invest. 6:1998;109-119.
22. Hall E. J. Radiobiology for the Radiologist. 1994;J B Lippincott, Philadelphia. p. 165-181.
23. Plum J., Daldrup T. [Distribution of digitoxin and their cardioactive metabolites in human heart and kidney tissue. A postmortem study]. Z Rechtsmed. 94:1985;257-272.
24. Aderjan R., Buhr H., Schmidt G. Investigation of cardiac glycoside levels in human post mortem blood and tissues determined by a special radioimmunoassay procedure. Arch Toxicol. 42:1979;107-114.
25. Dutta S., Marks B. H., Schoener E. P. Accumulation of radioactive cardiac glycosides by various brain regions in relation to the dysrhythmogenic effect. Br J Pharmacol. 59:1977;101-106.
26. Abang A. M. The clinical pharmacology of topoisomerase I inhibitors. Semin Hematol. 3:1998;13-21.
27. Sadzuka Y., Hirotsu S., Hirota S. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res. 90:1999;226-232.
28. Voutquenne L., Lavaud C., Massiot G., Sevenet T., Hadi H. A. Cytotoxic polyisoprenes and glycosides of long-chain fatty alcohols from Dimocarpus fumatus. Phytochemistry. 50:1999;63-69.
29. Thiagarajan D. G., Bennink M. R., Bourquin L. D., Kavas F. A. Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium. Am J Clin Nutr. 68:1998;1394-1399.
30. Ota T., Maeda M., Odashima S., Ninomiya-Tsuji J., Tatsuka M. G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells. Life Sci. 60:1997;39-44.
31. Mitaku S., Skaltsounis A. L., Tillequin F. Synthesis and anti-proliferative activity of 2-hydroxy-1,2-dihydroacronycine glycosides. Pharm Res. 13:1996;939-943.
32. Kolbel F., Schreiber V. The endogenous digitalis-like factor. Mol Cell Biochem. 160-161:1996;111-115.
33. Pamnani M. B., Chen S., Haddy F. J., Yuan C., Mo Z. Role of digitalis-like substance in the hypertension of streptozotocin-induced diabetes and simulated weightlessness in rats. Clin Exp Hypertens. 20:1998;509-521.
34. Pittenger G. L., Liu D., Vinik A. I. The apoptotic death of neuroblastoma cells caused by serum from patients with insulin-dependent diabetes and neuropathy may be Fas-mediated. J Neuroimmunol. 76:1997;153-160.
35. Haux J., Johnsen A. C., Steinkjer B., Egeberg K., Sundan A., Espevik T. The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis. Cancer Immunol Immunother. 48:1999;139-146.
36. Repke K. R.H., Benga Gh., Tager J. M. Biomembranes, Basic and Medical Research. 1988;Springer Verlag, Berlin. p. 161-173.
37. Repke K. R., Schon R., Megges R., Weiland J., Nissen E., Matthes E. Potential suitability of Na+/K(+)-transporting ATPase in pre-screens for anti-cancer agents. Anticancer Drug Des. 10:1995;177-187.
38. Sen C. K., Sashwati R., Packer L. Fas mediated apoptosis of human jurkat T-cells: intracellular events and potentiation by redox-active alpha-lipoic acid. Cell Death Differ. 6:1999;481-491.
39. Chien M. M., Zahradka K. E., Newell M. K., Freed J. H. Fas-induced B cell apoptosis requires an increase in free cytosolic magnesium as an early event. J Biol Chem. 274:1999;7059-7066.
40. Hughes F. M. Jr, Evans-Storms R. B., Cidlowski J. A. Evidence that non-caspase proteases are required for chromatin degradation during apoptosis. Cell Death Differ. 5:1998;1017-1027.
41. Repke K. R., Matthes E. Tamoxifen is a Na(+)-antagonistic inhibitor of Na+/K(+)-transporting ATPase from tumour and normal cells. J Enzyme Inhib. 8:1994;207-212.
42. Toma S., Ugolini D., Palumbo R. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? Int J Oncol. 15:1999;321-337.
43. Couldwell W. T., Hinton D. R., Surnock A. A. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res. 2:1996;619-622.
44. Baltuch G. H., Couldwell W. T., Villemure J. G., Yong V. W. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery. 33:1993;495-501.
45. Zhang W., Yamada H., Sakai N., Niikawa S., Nozawa Y. Enhancement of radiosensitivity by tamoxifen in C6 gliom cells. Neurosurgery. 31:1992;725-729.
46. Zhou B. N., Bahler B. D., Hofmann G. A., Mattern M. R., Johnson R. K., Kingston D. G. I. Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKC alpha-inhibitory activity. Nat Prod. 6:1998;1410-1412.
47. Koyama S., Takagi H., Otani A., Suzuma K., Nishimura K., Honda Y. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol. 127:1999;537-545.
48. Seo M. S., Kwak N., Ozaki H. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol. 154:1999;1743-1753.
49. McCarty M. F. Selenium, calcium channel blockers, and cancer risk - the Yin and Yang of apoptosis. Med Hypotheses. 50:1998;423-433.
50. Einhorn E. H. Testicular cancer: an oncological success story. Clin Cancer Res. 3:1997;2630-2632.